Health reform will be expensive. Just how expensive partly has to do with how we choose to finance it. Joseph Antos argues against limiting income tax deduction in favor of capping or eliminating the deduction for employer-sponsored health insurance, as the latter would do more to bend the cost-growth curve of health care going forward.
Kidney Cancer Association's live chat from the ASCO Annual Meeting attracts patient interest.
KCA partners with ASCO Cancer Foundation to support research.
If Congress were to take a vote on a health reform bill today, Democrats and Republicans would find a surprising level of agreement so much so that the broad outlines of a consensus plan already are taking shape. However, but they'd be required to pay for it by law.
A sister compound to Bayer and Onyx Pharmaceuticals' potential blockbuster Nexavar has showed promise against kidney cancer in a Phase II study.
My sister Sarah called me into her bedroom, and she sounded anxious. I remember it was just before her 17th birthday and she had discovered a lump in her tummy and asked me to feel it, wondering if she was imagining things. But she was right - there was a hard lump, the size of a tomato, just to the left of her belly button.
Pfizer announced today, at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting, the results of several clinical studies that may help identify patients who are more likely to benefit when treated with Sutent® (sunitinib malate) or axitinib (AG-013736), an investigational compound.
Swiss drug giant Novartis AG (NVS) Friday said it is close to getting approval to sell kidney cancer drug Afinitor in Europe.
KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor .
Will the next health-reform bill lock in a system of job-based health insurance or allow more individual choice and portability to fit a 21st century work force?